Lisata Therapeutics Inc. Cash Flow Conversion Efficiency
Lisata Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has a cash flow conversion efficiency ratio of -0.332x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.65 Million) by net assets ($7.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lisata Therapeutics Inc. (1993–2025)
Cash flow conversion efficiency of Lisata Therapeutics Inc. from 1993 to 2025. This chart illustrates how Lisata Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Lisata Therapeutics Inc. for real-time trading data and today's change.
Lisata Therapeutics Inc. Cash Flow Conversion Ratio Explained
Lisata Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lisata Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lisata Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see LSTA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energisme
PA:ALNRG
|
-1.376x |
|
Regenbogen AG
F:RGB
|
0.022x |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
-0.249x |
|
Daewoo SBI SPAC 1
KQ:215480
|
0.196x |
|
Minbos Resources Ltd
AU:MNB
|
-0.118x |
|
Ecocab Co. Ltd
KQ:128540
|
0.095x |
|
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
|
-0.267x |
|
Prodigy Gold NL
AU:PRX
|
-0.311x |
Annual Cash Flow Conversion Efficiency for Lisata Therapeutics Inc. (1993–2025)
The table below shows the annual cash flow conversion efficiency of Lisata Therapeutics Inc. from 1993 to 2025. Review LSTA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $14.60 Million | $-15.95 Million | -1.092x | -65.45% |
| 2024-12-31 | $29.32 Million | $-19.36 Million | -0.660x | -57.85% |
| 2023-12-31 | $47.89 Million | $-20.03 Million | -0.418x | -31.04% |
| 2022-12-31 | $66.32 Million | $-21.17 Million | -0.319x | -32.01% |
| 2021-12-31 | $92.00 Million | $-22.25 Million | -0.242x | +11.64% |
| 2020-12-31 | $32.24 Million | $-8.82 Million | -0.274x | +70.21% |
| 2019-12-31 | $20.55 Million | $-18.88 Million | -0.919x | -72.17% |
| 2018-12-31 | $37.45 Million | $-19.99 Million | -0.534x | -28.29% |
| 2017-12-31 | $50.19 Million | $-20.88 Million | -0.416x | +92.85% |
| 2016-12-31 | $4.07 Million | $-23.67 Million | -5.820x | -245.19% |
| 2015-12-31 | $23.28 Million | $-39.26 Million | -1.686x | -108.80% |
| 2014-12-31 | $58.07 Million | $-46.90 Million | -0.808x | -84.81% |
| 2013-12-31 | $62.03 Million | $-27.10 Million | -0.437x | -3.52% |
| 2012-12-31 | $32.82 Million | $-13.85 Million | -0.422x | -61.61% |
| 2011-12-31 | $80.13 Million | $-20.93 Million | -0.261x | -166.47% |
| 2010-12-31 | $86.49 Million | $-8.48 Million | -0.098x | +32.47% |
| 2009-12-31 | $59.59 Million | $-8.65 Million | -0.145x | +97.35% |
| 2008-12-31 | $863.18K | $-4.73 Million | -5.482x | -196.46% |
| 2007-12-31 | $3.32 Million | $-6.13 Million | -1.849x | +85.16% |
| 2006-12-31 | $292.11K | $-3.64 Million | -12.457x | -2814.98% |
| 2005-12-31 | $-1.82 Million | $-834.00K | 0.459x | -39.28% |
| 2004-12-31 | $-1.93 Million | $-1.46 Million | 0.756x | +11.11% |
| 2003-12-31 | $-1.50 Million | $-1.02 Million | 0.680x | +155.73% |
| 2002-12-31 | $-823.89K | $1.01 Million | -1.220x | -21.99% |
| 2001-12-31 | $373.73K | $-373.84K | -1.000x | -58.51% |
| 2000-12-31 | $3.13 Million | $-1.98 Million | -0.631x | -579.82% |
| 1999-12-31 | $3.92 Million | $-364.12K | -0.093x | -110.60% |
| 1998-12-31 | $-307.81K | $-269.60K | 0.876x | +87.60% |
| 1996-12-31 | $-651.71K | $-304.27K | 0.467x | -82.23% |
| 1995-12-31 | $-319.11K | $-838.44K | 2.627x | +807.11% |
| 1994-12-31 | $-2.90 Million | $-840.00K | 0.290x | -- |
| 1993-12-31 | $0.00 | $470.00K | x | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more